Neurobo pharmaceuticals, inc. (GEMP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating activities
Net loss

-4,730

-11,161

-3,430

-2,920

-3,801

-3,656

-6,079

-6,678

-7,224

-6,746

-8,671

-10,502

-7,496

-7,214

-3,878

-1,391

-2,103

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

159

-1,234

441

438

473

575

1,627

909

1,020

738

736

2,963

836

933

567

95

123

Non cash interest related to convertible notes - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

38

77

31

Non cash interest related to convertible notes – related party

-

-

-

-

-

-

-

-

-

-

-

-

-

0

57

121

78

Non-cash discount amortization on convertible notes to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

0

16

22

-55

Non-cash discount amortization on term loan

-

-

0

0

822

99

93

77

77

-

-

-

-

-

-

-

-

Revaluation of premium conversion derivative

-

-

-

-

-

-

-

-

-

-

-

-

-

0

243

629

-22

Depreciation

11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

lease liability principal payment

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use leased asset depreciation

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest upon conversion of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

0

892

-84

-159

Change in assets and liabilities, net of the effects of the reverse asset acquisition:
Prepaid expenses and other assets

1,202

-262

-178

-277

-107

-324

297

391

-168

-348

358

-47

-161

-477

384

149

-1

Accounts payable

637

-1,679

1,009

434

-810

-307

-218

-152

-1,304

-234

785

-17

1,473

1,130

236

353

-242

Accrued and other liabilities

987

1,009

14

-96

39

-1,148

590

-43

27

-945

151

890

-1,197

1,052

-659

-191

294

Net cash used in operating activities

-4,138

-214

-1,788

-1,867

-3,170

-4,113

-4,284

-6,278

-7,236

-6,760

-7,299

-6,619

-6,223

-

-

-

-

Investing activities
Purchases of property and equipment

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-4,138

-214

-1,788

-1,867

-3,170

-4,113

-4,284

-6,278

-7,236

-6,760

-7,299

-6,619

-6,223

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,056

Financing activities
Proceeds from issuance of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,601

50

Proceeds from issuance of convertible notes to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,399

101

Repayment of principal

-

-

0

0

-10,259

-

-

-

-

-

-

-

-

-

-

-

-

Exercise of stock options

-

-

-

-

-

0

61

0

23

0

28

10

3

-

-

-

-

Exercise of stock options

53

-

-

-

-

0

0

0

25,150

0

0

0

12,541

-

-

-

-

Issuance costs

-

-

-

-

-

-2

0

144

1,949

30

3

182

1,072

713

3,101

63

86

Net cash provided by financing activities

53

34,426

0

0

-10,259

-739

51

-144

23,224

-107

10,148

-172

11,472

-

-

-

-

Net decrease in cash and restricted cash

-4,087

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net foreign exchange difference

-22

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

65

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-13,429

-

-

-

15,988

-6,867

2,849

-6,791

5,249

-4,336

23,543

3,197

-1,991

Supplemental disclosure of cash flow information:
Cash paid for interest

-

-74

0

0

75

130

126

120

112

-

-

-

-

-

-

-

-

Supplemental non-cash financing transactions:
Net liabilities assumed in connection with the merger

-

-

-

-

-

-

-

-

144

-

86

-144

147

-

-

688

46

Redemption value change of Series A preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

0

67

150

149

Bifurcation of premium conversion derivative related to convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

496

9